Results 31 to 40 of about 22,494 (197)

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34⁺ cells to imatinib [PDF]

, 2009
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Hatziieremia, S., Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G., Mountford, J.C.   +4 more
core   +1 more source

Imatinib-induced interstitial pneumonitis – a literature review and case report [PDF]

, 2020
Imatinib is generally well tolerated, with mild common side effects such as nausea and vomiting, diarrhea, muscle cramps, fatigue, skin rash and edema; however, pulmonary complications are uncommon. A 73-year-old woman undergoing one month treatment with
Ciulei, George, Coste, Sorina Cezara, Cozma, Angela, Fabian, Ovidiu, Minciuna, Iulia, Muresan, Flaviu, Negrean, Vasile, Orasan, Olga Hilda, Para, Ioana, Sitar-Taut, Adela, Stefan, Andreea Maria, Tarmure, Simina, Urian, Laura   +12 more
core   +2 more sources

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells [PDF]

, 2011
Chronic myeloid leukaemia (CML) is maintained by a rare population of tyrosine kinase inhibitor (TKI)-insensitive malignant stem cells. Our long-term aim is to find a BcrAbl-independent drug that can be combined with a TKI to improve overall disease ...
A Quintas-Cardama, A Quintas-Cardama, A Quintas-Cardama, AJ Tipping, AJ Tipping, B Zhang, C Akgul, C Bellodi, G Gurel, H de Lavallade, H Konig, HG Jorgensen, HM Kantarjian, J Kuroda, KJ Aichberger, L Legros, M Copland, M Copland, NB Heaney, R Chen, R Tang, RG Powell, RM Stone, S Chu, SM Graham, SV Sharma, T Kobayashi, Y Chen   +27 more
core   +1 more source

Long-term follow-up of Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in children and adolescents managed at a single institution over a 20-year period [PDF]

, 2005
Chronic myeloid leukaemia (CML) is rare in childhood. In our Institution we managed 30 consecutive Ph+CML patients aged
DE CUIA MR, DEL GIUDICE, ILARIA, DIVERIO D, FOA, Roberto, GIONA, Fiorina, MANDELLI, Franco, MOLETI ML, TESTI, Anna Maria   +7 more
core   +1 more source

Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options [PDF]

, 2018
The onset of global epigenetic changes in chromatin that drive tumor proliferation and heterogeneity is a hallmark of many forms cancer. Identifying the epigenetic mechanisms that govern these changes and developing therapeutic approaches to modulate ...
Koschmieder, Steffen, Vetrie, David
core   +1 more source

A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome

BMC Cancer, 2010
Background About 80% of patients with GIST would experience tumor recurrence or metastasis after radical resection. The most common site of the metastasis is the liver. Imatinib mesylate has been proved effective for advanced GIST.
Jiang Ming, Zhou Lin, Yang Yu, Zhu Jiang, Hou Mei   +4 more
doaj   +1 more source

Renal phosphate loss in Iraqi chronic myeloid leukemia patients treated by imatinib mesylate

Iraqi Journal of Hematology, 2020
BACKGROUND: The use of BCR-ABL tyrosine kinase inhibitor imatinib mesylate improved outcomes for patients with chronic myeloid leukemia (CML). Hypophosphatemia is found to be associated with imatinib mesylate use; the exact mechanism of this is not clear
Huda A Al-Taee, Azhar K Athab, Ala Ali
doaj   +1 more source

Targeting SOS1 overcomes imatinib resistance with BCR-ABL independence through uptake transporter SLC22A4 in CML

Molecular Therapy: Oncolytics, 2021
Resistance to the BCR-ABL inhibitor imatinib mesylate poses a major problem for the treatment of chronic myeloid leukemia. Imatinib resistance often results from a secondary mutation in BCR-ABL that interferes with drug binding.
Yanjun Liu, Chuting Li, Rui Su, Zhao Yin, Guiping Huang, Juhua Yang, Zhendong Li, Keda Zhang, Jia Fei   +8 more
doaj   +1 more source

Management of imatinib-resistant CML patients [PDF]

, 2007
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option.
Branford S, Burger H, Burgess MR, Cortes J, Crossman LC, Donato NJ, Druker BJ, Gambacorti-Passerini C, Giles F, Hochhaus A, Hughes TP, Iacobucci I, Kantarjian H, Lahaye T, Mahon FX, Melo JV, O'Hare T, Quintas-Cardama A, Rousselot P, Sleijfer S, Soverini S, Weisberg E   +21 more
core   +1 more source

Evaluation of imatinib mesylate (Gleevec) on KAI1/CD82 gene expression in breast cancer MCF-7 cells using quantitative real-time PCR

Asian Pacific Journal of Tropical Biomedicine, 2016
Objective: To evaluate the effect of imatinib mesylate on cell viability, anti cancer effect through modulation of KAI1/CD82 gene expression in breast cancer MCF-7 cell line.
Seyed Ataollah Sadat Shandiz, Marjan Khosravani, Sepideh Mohammadi, Hassan Noorbazargan, Amir Mirzaie, Davoud Nouri Inanlou, Mojgan Dalirsaber Jalali, Hamidreza Jouzaghkar, Fahimeh Baghbani-Arani, Behta Keshavarz-Pakseresht   +9 more
doaj   +1 more source